Sumitovant Biopharma Ltd., in conjunction with parent company Sumitomo Pharma Co., Ltd. and Myovant Sciences, has entered into a definitive agreement pursuant to which Sumitovant will acquire all outstanding shares of Myovant not already owned by Sumitovant for $27.00 per share in cash.   This corresponds to a total transaction value of $1.7 billion on a fully diluted basis, and a total company value of $2.9 billion on a fully diluted basis. Sumitovant currently beneficially owns 52% of the is...